Imaging angiogenesis: Application and potential for drug development

Journal of the National Cancer Institute

Volumn 97, Issue 3, 2005, Pages 172-187

  Miller, Janet C ^a   Pien, Homer H ^a   Sahani, Dushyant ^a   Sorensen, A Gregory ^a   Thrall, James H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; BIOLOGICAL MARKER; CARBON 11; CARBOXYHEMOGLOBIN; COMBRETASTATIN A4 PHOSPHATE; ENDOGLIN; FIBRONECTIN; FLUORINE 18; GADOLINIUM PENTETATE; GELATINASE A; GLUCOCORTICOID; HEMOGLOBIN; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDIUM 111; IODINATED CONTRAST MEDIUM; IODINE 123; N ACETYLCOLCHINOL PHOSPHATE; OXYGEN 15; TECHNETIUM 99M; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB; VITRONECTIN RECEPTOR;

ACCURACY; ANALYTIC METHOD; ANGIOGENESIS; AREA UNDER THE CURVE; BLOOD VOLUME; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; CYTOTOXICITY; DENSITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TRANSPORT; ECHOGRAPHY; GLIOMA; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL ANALYSIS; MEDICAL ASSESSMENT; META ANALYSIS; METASTASIS POTENTIAL; MICROVASCULATURE; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RECTUM TUMOR; RELIABILITY; REPRODUCIBILITY; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE; SYSTEMATIC REVIEW; TIME; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; BLOOD FLOW VELOCITY; DRUG DESIGN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); RADIOGRAPHY; SCINTISCANNING; SYNTHESIS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BLOOD FLOW VELOCITY; BLOOD VOLUME; CLINICAL TRIALS; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 13744253539     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji023     Document Type: Review

References (135)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
2. Aiello L. Keeping in touch with angiogenesis. Nat Med 2000;6:379-81.
3. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000;5 Suppl 1:20-7.
4. Marx J. A boost for tumor starvation. Science 2003;301:452-4.
5. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8-14.
6. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and does not tell us. J Natl Cancer Inst 2002;94:883-93.
7. Costouros NG, Diehn FE, Libutti SK. Molecular imaging of tumor angiogenesis. J Cell Biochem Suppl 2002;39:72-8.
8. Anderson H, Price P, Blomley M, Leach MO, Workman P. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 2001;85:1085-93.
9. Padhani A. Functional MRI for anticancer therapy assessment. Eur J Cancer 2002;38:2116-27.
10. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002;38:2079-84.
11. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2:266-76.
12. Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
13. McDonald D, Choyke P. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-25.
14. Miles K. Tumour angiogenesis and its relation to contrast enhancement on computed tomography. Eur J Radiol 1999;30:198-205.
15. van Dijke CF, Brasch RC, Roberts TP, Weidner N, Mathur A, Shames DM, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996;198:813-8.
16. Anderson H, Price P. Clinical measurement of blood flow in tumours using positron emission tomography: a review. Nucl Med Commun 2002;23: 131-8.
17. Lin PC. Optical imaging and tumor angiogenesis. J Cell Biochem 2003; 90:484-91.
18. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-9.
19. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, Lei H, Meyerand ME, Grinberg OY, et al. Changes in oxygenation of intracranial tumors with carbogen: A BOLD MRI and EPR oximetry study. J Magn Reson Imaging 2002;16:511-21.
20. Yetkin FZ, Mendelsohn D. Hypoxia imaging in brain tumors. Neuroimaging Clin North Am 2002;12:537-52.
21. 2: determination of total and microvascular blood volume by MRI. Neoplasia 2003;5:330-8.
22. Dunn AK, Devor A, Bolay H, Andermann ML, Moskowitz MA, Dale AM, et al. Simultaneous imaging of total cerebral hemoglobin concentration, oxygenation, and blood flow during functional activation. Opt Lett 2003;28:28-30.
23. Schirner M, Menrad A, Stephens A, Frenzel T, Hauff P, Licha K. Molecular imaging of tumor angiogenesis. Ann N Y Acad Sci 2004;1014:67-75.
24. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10:1439-55.
25. Weissleder R, Bogdanov A Jr, Tung CH, Weinmann HJ. Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging. Bioconjug Chem 2001;12:213-9.
26. Tournier H, Hyacinthe R, Schneider M. Gadolinium-containing mixed micelle formulations: a new class of blood pool MRI/MRA contrast agents. Acad Radiol 2002;9 Suppl 1:S20-8.
27. Storrs RW, Tropper FD, Li HY, Song CK, Sipkins DA, Kuniyoshi JK, et al. Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J Magn Reson Imaging 1995;5:719-24.
28. Kobayashi H, Brechbiel MW. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging 2003;2:1-10.
29. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999;9:228-32.
30. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
31. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32.
32. Ferrara KW, Merritt CR, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 2000;7:824-39.
33. Li A, Miller E, Kilmer M, Brukilacchio T, Chaves T, Stott J, et al. Tomographic optical breast imaging guided by three-dimensional mammography. Appl Opt 2003;42:5181-91.
34. Ntziachristos V, Yodh AG, Schnall MD, Chance B. MRI-guided diffuse optical spectroscopy of malignant and benign breast lesions. Neoplasia 2002;4:347-54.
35. Groner W, Winkelman JW, Harris AG, Ince C, Bouma GJ, Messmer K, et al. Orthogonal polarization spectral imaging: a new method for study of the microcirculation. Nat Med 1999;5:1209-12.
36. Pahernik S, Harris AG, Schmitt-Sody M, Krasnici S, Goetz AE, Dellian M, et al. Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study. Br J Cancer 2002;86:1622-7.
37. Ntziachristos V, Yodh A, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A 2000;97:2767-72.
38. Cuccia DJ, Bevilacqua F, Durkin AJ, Merritt S, Tromberg BJ, Gulsen G, et al. In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration. Appl Opt 2003;42:2940-50.
39. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001;221:523-9.
40. Phelps ME, Huang SC, Hoffman EJ, Kuhl DE. Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. J Nucl Med 1979;20:328-34.
41. 15O and positron emission tomography. J Cereb Blood Flow Metab 1987;7:421-6.
42. 99mTc-DTPA-HSA SPECT. Radiat Med 1992;10:184-8.
43. Sabatini U, Celsis P, Viallard G, Rascol A, Marc-Vergnes JP. Quantitative assessment of cerebral blood volume by single-photon emission computed tomography. Stroke 1991;22:324-30.
44. Kiessling F, Krix M, Heilmann M, Vosseler S, Lichy M, Fink C, et al. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography. Invest Radiol 2003;38:516-24.
45. Rydland J, BjOrnerud A, Haugen O, Torheim G, Torres C, Kvistad KA, et al. New intravascular contrast agent applied to dynamic contrast enhanced MR imaging of human breast cancer. Acta Radiol 2003;44:275-83.
46. 15O]CO and positron emission tomography. Am J Physiol 1995;269:E1000-5.
47. Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med 2001;46:735-47.
48. Henry ME, Kaufman MJ, Lange N, Schmidt ME, Purcell S, Cote J, et al. Test-retest reliability of DSC MRI CBV mapping in healthy volunteers. Neuroreport 2001;12:1567-9.
49. Bremer C, Mustafa M, Bogdanov A, Ntziachristos N, Petrovsky A, Weissleder R. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens - a study in mice. Radiology 2003;226:214-20.
50. Weissleder R, Cheng HC, Marecos E, Kwong K, Bogdanov A Jr. Non-invasive in vivo mapping of tumour vascular and interstitial volume fractions. Eur J Cancer 1998;34:1448-54.
51. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 2001;218:562-9.
52. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. Dynamic CT measurement of cerebral blood flow: a validation study. AJNR Am J Neuroradiol 1999;20:63-73.
53. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. AJNR Am J Neuroradiol 2000;21:462-70.
54. Ostergaard L, Smith DF, Vestergaard-Poulsen P, Hansen SB, Gee AD, Gjedde A, et al. Absolute cerebral blood flow and blood volume measured by magnetic resonance imaging bolus tracking: comparison with positron emission tomography values. J Cereb Blood Flow Metab 1998;18:425-32.
55. Li KL, Zhu XP, Checkley DR, Tessier JJL, Hillier VF, Waterton JC, et al. Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. Br J Radiol 2003;76:39-51.
56. Perkio J, Aronen HJ, Kangasmaki A, Liu Y, Karonen J, Savolainen S, et al. Evaluation of four postprocessing methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging. Magn Reson Med 2002;47:973-81.
57. Wirestam R, Ryding E, Lindgren A, Geijer B, Holtas S, Stahlberg F. Absolute cerebral blood flow measured by dynamic susceptibility contrast MRI: a direct comparison with Xe-133 SPECT. Magma 2000;11:96-103.
58. Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJ, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 2003;76:153-62.
59. Kety S. Measurement of local blood flow by the exchange of an inert diffusible substance. Methods Med Res 1960;8:228-36.
60. 15O. II. Implementation and validation. J Nucl Med 1983;24:790-8.
61. Alpert NM, Eriksson L, Chang JY, Bergstrom M, Litton JE, Correia JA, et al. Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography. J Cereb Blood Flow Metab 1984;4:28-34.
62. Roberts DA, Detre JA, Bolinger L, Insko EK, Leigh JS Jr. Quantitative magnetic resonance imaging of human brain perfusion at 1.5 T using steady-state inversion of arterial water. Proc Natl Acad Sci U S A 1994; 91:33-7.
63. Roberts DA, Detre JA, Bolinger L, Insko EK, Lenkinski RE, Pentecost MJ, et al. Renal perfusion in humans: MR imaging with spin tagging of arterial water. Radiology 1995;196:281-6.
64. Roberts DA, Gefter WB, Hirsch JA, Rizi RR, Dougherty L, Lenkinski RE, et al. Pulmonary perfusion: respiratory-triggered three-dimensional MR imaging with arterial spin tagging-preliminary results in healthy volunteers. Radiology 1999;212:890-5.
65. 15O positron emission tomography in humans. J Cereb Blood Flow Metab 1993;13:748-54.
66. 15O positron emission tomography. J Cereb Blood Flow Metab 2002;22:1149-56.
67. Araujo LI, Lammertsma AA, Rhodes CG, McFalls EO, Iida H, Rechavia E, et al. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation 1991;83:875-85.
68. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992;52:1592-7.
69. Arbab AS, Aoki S, Toyama K, Miyazawa N, Kumagai H, Unreda T, et al. Quantitative measurement of regional cerebral blood flow with flow-sensitive alternating inversion recovery imaging: comparison with [iodine 123]-iodoamphetamin single photon emission CT. AJNR Am J Neuroradiol 2002;23:381-8.
70. Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228: 523-32.
71. Yen YF, Field AS, Martin EM, Ari N, Burdette JH, Moody DM, et al. Test-retest reproducibility of quantitative CBF measurements using FAIR perfusion MRI and acetazolamide challenge. Magn Reson Med 2002;47:921-8.
72. 99mTc-HMPAO SPECT. J Comput Assist Tomogr 2000;24:526-30.
73. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97:473-83.
74. 15O positron emission tomography. Neurol Res 2000; 22:457-64.
75. 15O positron emission tomography. AJNR Am J Neuroradiol 2003;24:419-26.
76. Gillard JH, Antoun NM, Burnet NG, Pickard JD. Reproducibility of quantitative CT perfusion imaging. Br J Radiol 2001;74:552-5.
77. Miles KA, Griffiths MR. Perfusion CT: a worthwhile enhancement? Br J Radiol 2003;76:220-31.
78. Carroll TJ, Rowley HA, Haughton VM. Automatic calculation of the arterial input function for cerebral perfusion imaging with MR imaging. Radiology 2003;227:593-600.
79. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 2001;14:457-63.
80. Sorensen A, Reimer P. Cerebral MR perfusion imaging: principles and current applications. New York (NY): Verlag; 2000.
81. Wei K, Le E, Bin JP, Coggins M, Thorpe J, Kaul S. Quantification of renal blood flow with contrast-enhanced ultrasound. J Am Coll Cardiol 2001;37:1135-40.
82. Krix M, Kiessling F, Farhan N, Schmidt K, Hoffend J, Delorme S. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med Biol 2003; 29:1421-30.
83. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
84. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002;15:154-63.
85. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
86. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-42.
87. Padhani AR, Hayes C, Landau S, Leach MO. Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 2002;15: 143-53.
88. Brix G, Bahner ML, Hoffmann U, Horvath A, Schreiber W. Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT - initial experience. Radiology 1999;210: 269-76.
89. Fuentes MA, Keith CJ, Griffiths M, Durbridge G, Miles KA. Hepatic haemodynamics: interrelationships between contrast enhancement and perfusion on CT and Doppler perfusion indices. Br J Radiol 2002;75:17-23.
90. Patlak CS, Fenstermacher JD. Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion. Am J Physiol 1975;229: 877-84.
91. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9: 653-60.
92. Curtet C, Maton F, Havet T, Slinkin M, Mishra A, Chatal JF, et al. Polylysine-Gd-DTPAn and polylysine-Gd-DOTAn coupled to anti-CEA F(ab′)2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Invest Radiol 1998;33:752-61.
93. Bogdanov A Jr, Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates results in signal amplification and can be used for MR imaging of molecular targets. Mol Imaging 2002;1:16-23.
94. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
95. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.
96. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998;25:1383-9.
97. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004;113:1684-91.
98. 3. Circulation 2003;108:336-41.
99. 3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63:5838-43.
100. 3-integrin-targeted nanoparticles. Circulation 2003; 108:2270-4.
101. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003;14:1274-7.
102. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
103. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17: 984-92.
104. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9:571-9.
105. Mayr NA, Hawighorst H, Yuh WT, Essig M, Magnotta VA, Knopp MV. MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome. J Magn Reson Imaging 1999;10:267-76.
106. George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001;88:1628-36.
107. de Vries A, Griebel J, Kremser C, Judmaier W, Gneiting T, Debbage P, et al. Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. Radiology 2000;217:385-91.
108. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351-6.
109. Hulka CA, Edmister WB, Smith BL, Tan L, Sgroi DC, Campbell T, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997;205:837-42.
110. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-49.
111. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-6.
112. Turetschek K, Floyd E, Shames DM, Roberts TP, Preda A, Novikov V, et al. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology. Magn Reson Med 2001;45: 880-6.
113. Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, et al. Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 1998;58:3598-602.
114. Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N. Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer 2002;95:835-42.
115. Hayashi K, Tozaki M, Sugisaki M, Yoshida N, Fukuda K, Tanabe H. Dynamic multislice helical CT of ameloblastoma and odontogenic keratocyst: correlation between contrast enhancement and angiogenesis. J Comput Assist Tomogr 2002;26:922-6.
116. Wang ZQ, Li JS, Lu GM, Zhang XH, Chen ZQ, Meng K. Correlation of CT enhancement, tumor angiogenesis and pathologic grading of pancreatic carcinoma. World J Gastroenterol 2003;9:2100-4.
117. Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004;14:309-17.
118. Jinzaki M, Tanimoto A, Mukai M, Ikeda E, Kobayashi S, Yuasa Y, et al. Double-phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr 2000;24:835-42.
119. Robinson S, McIntyre D, Checkley D, Tessier J, Howe F, Griffiths J, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88:1592-7.
120. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38.
121. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-31.
122. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
123. Morgan B, Thomas A, Drevs J, Hennig J, Buchert, M, Jivan, A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
124. Bhujwalla Z, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen P. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003; 9:355-62.
125. Delille J-P, Slanetz P, Yeh E, Halpern E, Kopans D, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging - pilot study. Radiology 2003; 228:63-9.
126. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 2001;218:365-74.
127. Mankoff D, Dunnwald L, Gralow J, Ellis G, Schubert E, Tseng J, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-14.
128. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30.
129. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7. Epub 2004 Jan 25.
130. Krix M, Kiessling F, Vosseler S, Farhan N, Mueller MM, Bohlen P, et al. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res 2003;63:8264-70.
131. Roberts T, Turetschek K, Preda A, Novikov V, Moeglich M, Shames D, et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol 2002;9 Suppl 2:S511-3.
132. Wetzel SG, Cha S, Johnson G, Lee P, Law M, Kasow DL, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224: 797-803.
133. Dawson B, Trapp R. Basic and clinical biostatistics. 3rd ed. New York (NY): McGraw-Hill; 2001.
134. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003;30:32-8.
135. Ostergaard L, Hochberg FH, Rabinov JD, Sorensen AG, Lev M, Kim L, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999;90:300-5.